[Research Report] The pancreatic cancer therapy market is expected to reach US$ 4056.4 million by 2025 from US$ 2011.2 million in 2017; it is estimated to grow at a CAGR of 8.1% from 2018 to 2025.
Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.
Lucrative Regional Markets for Pancreatic Cancer Therapy
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Rise in Number of Patients Suffering with Pancreatic Cancer
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.
Type Insights
Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.
Global Pancreatic Cancer Therapy Market, by Type – 2017 and 2025
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Therapy Insights
Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pancreatic Cancer Therapy Market: Strategic Insights
Market Size Value in US$ 2011.2 Million in 2017 Market Size Value by US$ 4056.4 Million by 2025 Growth rate CAGR of 8.1% from 2018-2025 Forecast Period 2018-2025 Base Year 2018
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pancreatic Cancer Therapy Market: Strategic Insights
| Market Size Value in | US$ 2011.2 Million in 2017 |
| Market Size Value by | US$ 4056.4 Million by 2025 |
| Growth rate | CAGR of 8.1% from 2018-2025 |
| Forecast Period | 2018-2025 |
| Base Year | 2018 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Organic strategies are the more commonly adopted strategies by companies in the pancreatic cancer therpay market, which enables them expand their global footprints, and product and service portfolios. The market players have also adopted organic strategies such as product approvals, clinical trials and others strategies have enabled them to enlarge their global customer base, which also permits them to maintain their brand name globally.
Global Pancreatic Cancer Therapy Market – By Type
- Exocrine Pancreatic Cancer
- Endocrine Pancreatic Cancer
Global Pancreatic Cancer Therapy Market– By Therapy
- Biologics Therapy
- Chemotherapy
- Others
Global Pancreatic Cancer Therapy Market– By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
South and Central America
- Brazil
- Argentina
Company Profiles
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Amgen Inc
- Novartis AG
- Celgene Corporation
- Merck & Co., Inc
- Pharmacyte Biotech Inc
- Clovis Oncology
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type , Therapy and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
TABLE OF CONTENTS
1. INTRODUCTION 18
1.1 SCOPE OF THE STUDY 18
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 18
2. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY TAKEAWAYS 19
3. GLOBAL PANCREATIC CANCER THERAPY MARKET - MARKET LANDSCAPE 21
3.1 OVERVIEW 21
3.2 MARKET SEGMENTATION 21
3.3 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY TYPE 22
3.4 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY THERAPY 22
3.5 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY 23
3.6 PEST ANALYSIS 24
3.6.1 North America - PEST Analysis 24
3.6.2 Europe- PEST Analysis 26
3.6.3 Asia Pacific- PEST Analysis 28
3.6.4 Middle East And Africa- PEST Analysis 30
3.6.5 South and Central America - PEST Analysis 32
4. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY MARKET DYNAMICS 34
4.1 KEY MARKET DRIVERS 34
4.1.1 Rise in Number of Patients Suffering with Pancreatic Cancer 34
4.1.2 Increasing Healthcare Expenditures for Pancreatic Drugs 34
4.1.3 Increase in Number of Therapies Launched in the Market 35
4.2 KEY MARKET RESTRAINTS 35
4.2.1 Side Effects of the Therapies 35
4.2.2 Low Success Rate of Treatments 35
4.3 KEY MARKET OPPORTUNITIES 36
4.3.1 Development of Efficient Therapy for Pancreatic Cancer Treatment 36
4.4 FUTURE TRENDS 36
4.4.1 Rapid Adoption of Combination Therapy Over Monotherapy 36
4.5 IMPACT ANALYSIS 37
5. PANCREATIC CANCER THERAPY MARKET - GLOBAL ANALYSIS 38
5.1 GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS 38
5.2 GLOBAL PANCREATIC CANCER THERAPY MARKET, BY GEOGRAPHY - FORECASTS AND ANALYSIS 39
5.3 EXPERT OPINIONS 40
6. PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY TYPE 41
6.1 OVERVIEW 41
6.1.1 Endocrine Pancreatic Cancer 42
6.1.2 Overview 42
6.1.3 Global Endocrine Pancreatic Cancer Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 42
6.1.4 Exocrine Pancreatic Cancer 43
6.1.4.1 Overview 43
6.1.4.2 Global Exocrine Pancreatic Cancer Therapy market Revenue and Forecasts to 2025 (US$ Mn) 43
7. GLOBAL PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY THERAPY 44
7.1 OVERVIEW 44
7.2 BIOLOGIC THERAPY 45
7.2.1 Overview 45
7.2.2 Global Biologic Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 45
7.3 CHEMOTHERAPY 46
7.3.1 Overview 46
7.3.2 Global Chemotherapy Market Revenue and Forecasts to 2025 (US$ Mn) 46
7.4 OTHERS 47
7.4.1 Overview 47
7.4.2 Global Others Market Revenue and Forecasts to 2025 (US$ Mn) 47
8. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 48
8.1 OVERVIEW 48
8.2 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
8.3 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
8.4 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
8.5 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
8.6 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 51
8.7 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
8.7.1 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 52
8.7.2 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 53
8.8 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
8.9 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
8.9.1 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 55
8.9.2 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 55
8.10 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
8.11 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
8.11.1 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 57
8.11.2 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 57
9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 58
9.1 OVERVIEW 58
9.2 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
9.3 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
9.4 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
9.5 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
9.6 GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 61
9.6.1 Germany Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 62
9.6.2 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 62
9.6.3 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 63
9.7 UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 63
9.7.1 UK Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 64
9.7.2 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 64
9.7.3 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 65
9.8 FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
9.8.1 France Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 66
9.8.2 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 67
9.8.3 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 67
10. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 68
10.1 OVERVIEW 68
10.2 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
10.3 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
10.4 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
10.5 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
10.6 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
10.7 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
10.7.1 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 72
10.7.2 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 72
10.8 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
10.9 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
10.9.1 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 74
10.9.2 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 74
10.10 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 75
10.11 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
10.11.1 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 76
10.11.2 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 77
11. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 78
11.1 OVERVIEW 78
11.2 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
11.3 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
11.4 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
11.5 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
11.6 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
11.7 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
11.7.1 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 82
11.7.2 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 82
11.8 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 82
11.9 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
11.9.1 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 83
11.9.2 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 84
11.10 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 84
11.11 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
11.11.1 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 85
11.11.2 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 86
12. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 87
12.1 OVERVIEW 87
12.2 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
12.3 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
12.4 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
12.5 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
12.6 BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
12.6.1 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025 (US$ Mn) 90
12.6.2 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 91
12.6.3 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 91
13. PANCREATIC CANCER THERAPY MARKET -INDUSTRY LANDSCAPE 92
13.1 OVERVIEW 92
13.2 GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
13.3 ORGANIC DEVELOPMENTS 92
13.3.1 Overview 92
13.4 ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
13.5 CLINICAL TRIALS 93
13.5.1 Recent Clinical Trials By Players In The Pancreatic Cancer Therapy Market 93
13.6 PRODUCT APPROVAL 94
13.6.1 Recent Product Approval By Players In The Pancreatic Cancer Therapy Market 94
13.7 OTHERS 94
13.7.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 94
13.8 INORGANIC DEVELOPMENTS 95
13.8.1 Overview 95
13.9 INORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95
13.10 COLLABORATION 96
13.10.1 Recent Collaborations by Players in the Pancreatic Cancer Therapy Market 96
13.11 OTHERS 96
13.11.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 96
14. PANCREATIC CANCER THERAPY MARKET -KEY COMPANY PROFILES 97
14.1 ELI LILLY AND COMPANY 97
14.1.1 Key Facts 97
14.1.2 Business Description 97
14.1.3 Financial Overview 98
14.1.4 Product Portfolio 98
14.1.5 SWOT Analysis 98
14.1.6 Key Developments 99
14.2 F. HOFFMANN-LA ROCHE LTD. 100
14.2.1 Key Facts 100
14.2.2 Business Description 100
14.2.3 Financial Overview 101
14.2.4 Product Portfolio 101
14.2.5 Product Pipeline 101
14.2.6 SWOT Analysis 102
14.2.7 Key Developments 102
14.3 AMGEN INC. 103
14.3.1 Key Facts 103
14.3.2 Business Description 103
14.3.3 Financial Overview 104
14.3.4 Product Portfolio 104
14.3.5 Product Pipeline 104
14.3.6 SWOT Analysis 105
14.3.7 Key Developments 105
14.4 NOVARTIS AG 106
14.4.1 Key Facts 106
14.4.2 Business Description 106
14.4.3 Financial Overview 107
14.4.4 Product Portfolio 107
14.4.5 Product Pipeline 107
14.4.6 SWOT Analysis 108
14.4.7 Key Developments 108
14.5 CELGENE CORPORATION 109
14.5.1 Key Facts 109
14.5.2 Business Description 109
14.5.3 Financial Overview 110
14.5.4 Product Portfolio 110
14.5.5 SWOT Analysis 110
14.5.6 Key Developments 111
14.6 MERCK & CO., INC. 112
14.6.1 Key Facts 112
14.6.2 Business Description 112
14.6.3 Financial Overview 113
14.6.4 Product Portfolio 113
14.6.5 Product Pipeline 113
14.6.6 SWOT Analysis 114
14.6.7 Key Developments 114
14.7 PHARMACYTE BIOTECH INC. 116
14.7.1 Key Facts 116
14.7.2 Business Description 116
14.7.3 Financial Overview 117
14.7.4 Product Portfolio 117
14.7.5 SWOT Analysis 117
14.7.6 Key Developments 118
14.8 CLOVIS ONCOLOGY 119
14.8.1 Key Facts 119
14.8.2 Business Description 119
14.8.3 Financial Overview 120
14.8.4 Product Portfolio 120
14.8.5 SWOT Analysis 120
14.8.6 Key Developments 120
14.9 TEVA PHARMACEUTICAL INDUSTRIES LTD 121
14.9.1 Key Facts 121
14.9.2 Business Description 121
14.9.3 Financial Overview 122
14.9.4 Product Portfolio 122
14.9.5 SWOT Analysis 122
14.9.6 Key Developments 122
14.10 PFIZER INC. 123
14.10.1 Key Facts 123
14.10.2 Business Description 123
14.10.3 Financial Overview 124
14.10.4 Product Portfolio 124
14.10.5 SWOT Analysis 124
14.10.6 Key Developments 125
15. APPENDIX 126
15.1 ABOUT THE INSIGHT PARTNERS 126
15.2 GLOSSARY OF TERMS 127
15.3 METHODOLOGY 129
15.3.1 Coverage 130
15.3.2 Secondary Research 131
15.3.3 Primary Research 131
LIST OF TABLES
TABLE 1. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
TABLE 2. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
TABLE 3. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 52
TABLE 4. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 53
TABLE 5. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 55
TABLE 6. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 55
TABLE 7. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 57
TABLE 8. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 57
TABLE 9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
TABLE 10. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
TABLE 11. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 62
TABLE 12. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 63
TABLE 13. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 64
TABLE 14. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 65
TABLE 15. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 67
TABLE 16. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 67
TABLE 17. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
TABLE 18. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
TABLE 19. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
TABLE 20. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 72
TABLE 21. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 72
TABLE 22. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 74
TABLE 23. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 74
TABLE 24. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 76
TABLE 25. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 77
TABLE 26. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
TABLE 27. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
TABLE 28. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 82
TABLE 29. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 82
TABLE 30. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 83
TABLE 31. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 84
TABLE 32. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 85
TABLE 33. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 86
TABLE 34. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
TABLE 35. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
TABLE 36. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 91
TABLE 37. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$MN) 91
TABLE 38. RECENT CLINICAL TRIALS IN THE PANCREATIC CANCER THERAPY MARKET 93
TABLE 39. RECENT PRODUCT APPROVAL IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 40. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 41. RECENT COLLABORATIONS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 42. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 43. GLOSSARY OF TERMS, PANCREATIC CANCER THERAPY MARKET 127
LIST OF FIGURES
FIGURE 1. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET, REVENUE (US$ MN), BY GEOGRAPHY 2018 & 2025 19
FIGURE 2. GLOBAL PANCREATIC CANCER THERAPY MARKET BY TYPE, MARKET SHARE (%), 2017 20
FIGURE 3. GLOBAL PANCREATIC CANCER THERAPY MARKET BY THERAPY, MARKET SHARE (%), 2017 20
FIGURE 4. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION 21
FIGURE 5. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION, BY REGION 22
FIGURE 6. NORTH AMERICA PEST ANALYSIS 24
FIGURE 7. EUROPE PEST ANALYSIS 26
FIGURE 8. ASIA PACIFIC PEST ANALYSIS 28
FIGURE 9. MIDDLE EAST AND AFRICA PEST ANALYSIS 30
FIGURE 10. SOUTH AND CENTRAL AMERICA PEST ANALYSIS 32
FIGURE 11. PANCREATIC CANCER THERAPY MARKET IMPACT ANALYSIS OF DRIVER AND RESTRAINTS 37
FIGURE 12. GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS - 2017- 2025 38
FIGURE 13. GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY FORECASTS AND ANALYSIS - 2017- 2025 39
FIGURE 14. GLOBAL PANCREATIC CANCER THERAPY MARKET BREAKDOWN, BY PRODUCT 2017 & 2025 (%) 41
FIGURE 15. GLOBAL ENDOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 42
FIGURE 16. GLOBAL EXOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 43
FIGURE 17. GLOBAL PANCREATIC CANCER THERAPY MARKET SHARE, BY THERAPY 2017 & 2025 (%) 44
FIGURE 18. GLOBAL BIOLOGIC THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 45
FIGURE 19. GLOBAL CHEMOTHERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 46
FIGURE 20. GLOBAL OTHERS MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 47
FIGURE 21. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 48
FIGURE 22. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
FIGURE 23. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
FIGURE 24. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
FIGURE 25. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
FIGURE 26. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
FIGURE 27. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 58
FIGURE 28. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
FIGURE 29. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
FIGURE 30. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 62
FIGURE 31. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 64
FIGURE 32. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
FIGURE 33. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 68
FIGURE 34. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
FIGURE 35. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
FIGURE 36. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
FIGURE 37. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
FIGURE 38. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 78
FIGURE 39. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
FIGURE 40. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
FIGURE 41. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
FIGURE 42. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
FIGURE 43. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
FIGURE 44. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 87
FIGURE 45. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
FIGURE 46. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
FIGURE 47. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
FIGURE 48. GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
FIGURE 49. ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
FIGURE 50. INORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95
The List of Companies
1. Eli Lilly and Company
2. F. Hoffmann-La Roche AG
3. Celgene Corporation
4. Amgen Inc.
5. Novartis AG
6. Pharmacyte Biotech Inc.
7. Clovis Oncology
8. Teva Pharmaceutical Industries Ltd.
9. Pfizer Inc.
10. Merck & Co., Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Pancreatic Cancer Therapy Market
Aug 2018
Colonoscopes Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Fiber Optic Colonoscopy Devices, Video Colonoscopy Devices); Application (Colorectal Cancer, Lynch Syndrome, Ulcerative Colitis, Crohn's Disease, Polyp); End User (Hospitals, Ambulatory Surgery Center, Others), and Geography
Aug 2018
Noninvasive Fat Reduction Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Cryolipolysis, Laser Lipolysis, Ultrasound, and Others), End User (Hospitals, Dermatology Clinics & Cosmetic Clinics, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2018
Medical Ultrasound Flow Meter Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Implementation Type (Clamp-On, Inline, and Others), Technology (Doppler, Transit Time, and Hybrid), Application (Heart and Lung Machines, Extracorporeal Membrane Oxygenation, Perfusion, Organ Transportation Systems, and Others), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Research Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2018
Rapid Test Kits Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Rapid Antigen Testing, Rapid Antibody Testing, and Others), Product (Over-the-Counter Rapid Testing Kit and Professional Rapid Testing Kit), Technology (Lateral Flow Assay, Solid Phase, Agglutination, Immunospot Assay, and Cellular Component-Based), Application (Blood Glucose Testing, Infectious Disease Testing, Pregnancy and Fertility, Cardiometabolic Testing, and Others), End User (Hospital and Clinics, Home Care, Diagnostics Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2018
Osteoarthritis Therapy Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type [Transcutaneous Electrical Nerve Stimulation (TENS), Occupational Therapy, Physical Therapy, Platelet-Rich Plasma Therapy and Stromal Vascular Fraction, Prolotherapy, and Others], Disease Indication (Knee Osteoarthritis, Spine Osteoarthritis, Foot and Ankle Osteoarthritis, Shoulder Osteoarthritis, Hand Osteoarthritis, and Others), End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2018
Bariatric Surgeries Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type [Adjustable Gastric Bands (AGB), Sleeve Gastrectomy, Gastric Bypass, Biliopancreatic Diversion with Duodenal Switch (BPD-DS), and Others], End User (Hospitals and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2018
Post-Acute Care Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Service Type (Skilled Nursing Facilities, Inpatient Rehabilitation Facilities, Long-Term Care Hospitals, Home Health Agency, and Others), Age (Elderly, Adult, and Others), Disease Conditions (Amputations, Wound Management, Brain Injury and Spinal Cord Injury, Neurological Disorders, and Others), and Geography
Aug 2018
Lung Cancer Therapy Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)